Douglas Mapel, ATS 2021: The Rate of ED Visits in Patients with COPD in the IMPACT Trial

It was a pleasure to meet with Dr Douglas Mapel (Northern Arizona Pulmonary Associates – Critical Care, Flagstaff, AZ, US) to talk around his abstract on ‘Reduction in Emergency Department (ED) Visits in Patients with Chronic Obstructive Pulmonary Disease (COPD): Analysis of the IMPACT Trial.‘, which was presented at ATS 2021 International Conference, 14-19 May, 2021.

Questions

1. How substantial a health burden are emergency department (ED) visits associated with COPD? (0:25)
2. What did the IMPACT trial teach us about the efficacy and safety of single inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)? (0:47)
3. What were the findings of the analysis of the annual rate of ED visits in the IMPACT trial? (1:51)
4. What is the clinical significance of these findings? (2:30)
5. How can we further refine the role of inhaled corticosteroids in COPD patients? (3:12)

Disclosures: Douglas Mapel has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.

Filmed as a highlight of ATS 2021 (Virtual).